Cargando…

Cumulative Laxation Response with Methylnaltrexone: Implications for Hospitalized Patients with Advanced Illness and Opioid-Induced Constipation

BACKGROUND: Opioid-induced constipation (OIC) may increase the risk of fecal impaction and mortality in patients with advanced illness. Methylnaltrexone (MNTX) is efficacious for OIC. OBJECTIVE: The purpose of this analysis was to evaluate cumulative rescue-free laxation response with repeat MNTX do...

Descripción completa

Detalles Bibliográficos
Autores principales:	Farchadi, David, Slatkin, Neal E., Stambler, Nancy, Israel, Robert J., Matus, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981808/ https://www.ncbi.nlm.nih.gov/pubmed/36875317 http://dx.doi.org/10.1016/j.curtheres.2023.100694

Ejemplares similares

Impact of Patient Subgroups on the Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients with Advanced Illness
por: Mehta, Neel, et al.
Publicado: (2023)

The Influence of Age on Central Effects of Methylnaltrexone in Patients with Opioid-Induced Constipation
por: Liao, Solomon S., et al.
Publicado: (2021)

Safety of oral methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain
por: Rauck, Richard L, et al.
Publicado: (2018)

Correction to: The Influence of Age on Central Effects of Methylnaltrexone in Patients with Opioid-Induced Constipation
por: Liao, Solomon S., et al.
Publicado: (2021)

Methylnaltrexone Treatment for Opioid-Induced Constipation in Patients with and without Cancer: Effect of Initial Dose
por: Chamberlain, Bruce H, et al.
Publicado: (2023)

Subcutaneous Methylnaltrexone as Treatment for Opioid-Induced Constipation in Patients with Advanced Cancer and Noncancer Illnesses: A Post Hoc Analysis of Two Clinical Trials
por: Shah, Eric D, et al.
Publicado: (2023)

Subcutaneous Methylnaltrexone for Treatment of Opioid-Induced Constipation in Cancer versus Noncancer Patients: An Analysis of Efficacy and Safety Variables from Two Studies
por: Chamberlain, Bruce H, et al.
Publicado: (2021)

Attrition of methylnaltrexone treatment-emergent adverse events in patients with chronic noncancer pain and opioid-induced constipation: a post hoc pooled analysis of two clinical trials
por: Mehta, Neel, et al.
Publicado: (2023)

Reductions in All-Cause Mortality Associated with the Use of Methylnaltrexone for Opioid-Induced Bowel Disorders: A Pooled Analysis
por: Webster, Lynn R, et al.
Publicado: (2022)

Opioid-Induced Constipation in Advanced Illness: Safety and Efficacy of Methylnaltrexone Bromide
por: Bader, S., et al.
Publicado: (2011)

Managing opioid-induced constipation in advanced illness: focus on methylnaltrexone bromide
por: Clemens, Katri Elina, et al.
Publicado: (2010)

Methylnaltrexone in the treatment of opioid-induced constipation
por: Meerveld, Beverley Greenwood-Van, et al.
Publicado: (2008)

The influence of brain metastases on the central nervous system effects of methylnaltrexone: a post hoc analysis of 3 randomized, double-blind studies
por: Brenner, Darren M., et al.
Publicado: (2021)

Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation
por: Deibert, Peter, et al.
Publicado: (2010)

Methylnaltrexone and Naloxone for Opioid-induced Constipation in the Critical Care Setting
por: Saini, Harneel S, et al.
Publicado: (2020)

Oral methylnaltrexone does not negatively impact analgesia in patients with opioid-induced constipation and chronic noncancer pain
por: Webster, Lynn R, et al.
Publicado: (2018)

Fixed-Dose Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: Results of a Randomized, Placebo-Controlled Study and Open-Label Extension
por: Bull, Janet, et al.
Publicado: (2015)

Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexone
por: Neefjes, Elisabeth CW, et al.
Publicado: (2014)

Oral methylnaltrexone is efficacious and well tolerated for the treatment of opioid-induced constipation in patients with chronic noncancer pain receiving concomitant methadone
por: Webster, Lynn R, et al.
Publicado: (2018)

Prophylactic use of laxative for constipation in critically ill patients
por: Masri, Y, et al.
Publicado: (2010)

Prophylactic use of laxative for constipation in critically ill patients
por: Masri, Yasser, et al.
Publicado: (2010)

Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain
por: Webster, Lynn R, et al.
Publicado: (2015)

Methylnaltrexone for opioid-induced constipation: review and meta-analyses for objective plus subjective efficacy and safety outcomes
por: Siemens, Waldemar, et al.
Publicado: (2016)

Efficacy and Safety of Methylnaltrexone for the Treatment of Opioid-Induced Constipation: A Meta-analysis of Randomized Controlled Trials
por: Zhang, Ying-Ying, et al.
Publicado: (2021)

Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain [Corrigendum]
Publicado: (2018)

Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients With Chronic Noncancer Pain: A Placebo Crossover Analysis
por: Viscusi, Eugene R., et al.
Publicado: (2016)

Methylnaltrexone for the treatment of opioid-induced constipation and gastrointestinal stasis in intensive care patients. Results from the MOTION trial
por: Patel, Parind B., et al.
Publicado: (2020)

Long-Term Safety and Efficacy of Subcutaneous Methylnaltrexone in Patients with Opioid-Induced Constipation and Chronic Noncancer Pain: A Phase 3, Open-Label Trial
por: Webster, Lynn R., et al.
Publicado: (2017)

Laxatives Do Not Improve Symptoms of Opioid-Induced Constipation: Results of a Patient Survey
por: Emmanuel, Anton, et al.
Publicado: (2017)

Methylnaltrexone: Peripherally Acting µ-Opioid Receptor Antagonist
por: Uritsky, Tanya J.
Publicado: (2019)

Protocol for a randomised control trial of methylnaltrexone for the treatment of opioid-induced constipation and gastrointestinal stasis in intensive care patients (MOTION)
por: Patel, Parind B, et al.
Publicado: (2016)

Opioid-Induced Constipation: Cost Impact of Approved Medications in the Emergency Department
por: Peacock, W. Frank, et al.
Publicado: (2022)

Ischemic colitis in an infant with constipation treated with stimulant laxative
por: Sakaguchi, Hirotaka, et al.
Publicado: (2020)

A Nationwide Hospital Claims Database Analysis of Real-World Patterns of Laxative Use for Opioid-Induced Constipation in Japanese Patients with Cancer
por: Higashibata, Takahiro, et al.
Publicado: (2023)

Laxative effects of agarwood on low-fiber diet-induced constipation in rats
por: Kakino, Mamoru, et al.
Publicado: (2010)

Laxative effects of Salecan on normal and two models of experimental constipated mice
por: Zhou, Mengyi, et al.
Publicado: (2013)

Laxative effects of fermented rice extract in rats with loperamide-induced constipation
por: CHOI, JAE-SUK, et al.
Publicado: (2014)

Colonic response to laxative ingestion as assessed by MRI differs in constipated irritable bowel syndrome compared to functional constipation
por: Lam, C., et al.
Publicado: (2016)

Cellular Mechanisms Underlying the Laxative Effect of Flavonol Naringenin on Rat Constipation Model
por: Yang, Zi-Huan, et al.
Publicado: (2008)

Laxative effects of partially defatted flaxseed meal on normal and experimental constipated mice
por: Xu, Jiqu, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_72pjiju6tp4ctfncs181a0fsnf